Company: PACB
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001299130-25-000090
Chunk: 62

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 62
---
 than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party’s interest in the transaction. Our Audit Committee has reviewed certain types of related party transactions that it has deemed pre-approved even if the aggregate amount involved will exceed $120,000, including employment of executive officers, director compensation, certain transactions with other organizations involving the purchase or sale of products or services in the ordinary course of business, transactions where all stockholders receive proportional benefits, transactions involving competitive bids, regulated transactions and certain banking-related services.

#### Related Party Transactions
In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements discussed above, during 2024, we were party to the following transactions in which the amount involved exceeded or will exceed $120,000, and in which any director, executive officer or holder of more than 5% of any class of our voting stock, or any member of the immediate family of or entities affiliated with any of them, had or will have a material interest.

4D Molecular Therapeutics . John F. Milligan is the chairman of the board of directors of 4D Molecular Therapeutics. For the year ended December 31, 2024, we recognized revenue relating to 4D Molecular Therapeutics with a total value of approximately $191,000. As of December 31, 2024, approximately $57,000 out of our accounts receivable balance of $27,524,000 was related to 4D Molecular Therapeutics.

Stanford University. Randy Livingston is the Vice President for Business Affairs and Chief Financial Officer of Stanford University. Lucy Shapiro, Ph.D. is the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University’s School of Medicine. Hannah A. Valantine, M.D. is a Professor of Medicine (Cardiovascular) at the Stanford University Medical Center. For the years ended December 31, 2024 and 2023, we recognized revenue relating to Stanford University with a total value of approximately $346,000 and $960,000, respectively. As of December 31, 2024 and 2023, approximately $52,000 and $147,000, respectively, out of our accounts receivable balance of $27,524,000 and $36,615,000, respectively, was related to Stanford University.

Other Transactions. We have granted stock options and RSUs to our executive officers and certain of our directors. See the sections titled “Executive Compensation